Active drug shortages in the United States climbed to 227 in the second quarter of 2026, the third consecutive quarterly increase, as a severe shortage of the cancer chemotherapy drug ifosfamide emerged due to manufacturing quality problems and a persistent scarcity of CT imaging contrast agents continued to delay diagnostic procedures at hospitals and imaging centers across the country. The figures come from the American Society of Health-System Pharmacists (ASHP) and the University of Utah Drug Information Service, the two bodies that have tracked U.S. drug shortages since 2001.
While 227 active shortages is significantly below the record of 323 set in the first quarter of 2024, the steady upward trend of the past three quarters signals that the underlying structural vulnerabilities in U.S. pharmaceutical supply have not been resolved.
Why This Matters
Drug shortages are not an administrative inconvenience. When a hospital cannot obtain ifosfamide, oncologists treating testicular cancer or sarcoma must delay curative regimens or substitute less effective alternatives. When CT contrast agents are scarce, radiologists and emergency physicians must ration imaging procedures, potentially delaying cancer detection, missing strokes, or deferring cardiac evaluations for patients who cannot wait.
"When a drug shortage involves therapeutic agents for treating cancer, the consequences could be dire, such as increased medication errors, adverse effects, poor outcomes, and even death," as the pharmacy literature on oncology drug shortages has consistently documented. For patients awaiting cancer confirmation, stroke evaluation, or diagnostic imaging, shortages translate directly into delayed diagnoses and care gaps that compound over time.
The shortage environment also falls disproportionately on hospital pharmacists, who must locate alternatives, coordinate with prescribers to modify treatment plans, and document rationing decisions that no patient-facing member of the care team wants to make.
What We Know So Far
According to the ASHP Q2 2026 drug shortage statistics and AJMC analysis published July 20, 2026:
The 227 active shortages represent the third consecutive quarterly increase after a partial recovery from the 2024 peak. Central nervous system medications are the largest category of active shortages, followed by antimicrobials, with chemotherapy and hormone agents tied for third.
Nearly half of all new drug shortages in 2026 (48%) involve sole-source products: drugs made by only one manufacturer. This is one of the most important structural vulnerabilities in U.S. pharmaceutical supply. When a sole-source manufacturer faces a quality problem, contamination finding, facility shutdown, or supply disruption, there is no backup supplier to absorb demand. The entire domestic supply of that medication disappears simultaneously.
Ten percent of all new 2026 shortages involve CT and MRI contrast agents, which are essential for a wide range of diagnostic procedures including cancer staging, stroke diagnosis, pulmonary embolism evaluation, coronary artery imaging, and kidney function assessment. Contrast shortages directly delay or prevent these procedures at hospitals that cannot obtain adequate supply.
The most acute new shortage this quarter is ifosfamide, a chemotherapy drug used in curative treatment regimens for testicular cancer, soft tissue sarcoma, and pediatric Ewing sarcoma. The shortage developed after manufacturing quality problems surfaced at a key supplier. Ifosfamide is used in some of oncology's most curative contexts: for many men with metastatic testicular cancer, ifosfamide-containing regimens can achieve long-term remission or cure even after prior treatment has failed.
Sixteen percent of active shortages involve controlled substances, which directly affects patients managing chronic pain or ADHD, who may struggle to fill monthly prescriptions, and health systems that need adequate supply for scheduled surgeries and procedures.
Where the Impact Is Highest
The contrast agent shortage hits every hospital and outpatient imaging center that performs CT or MRI scans. In large hospital systems, contrast agents are typically managed through formulary protocols and rationing committees that prioritize the most urgent clinical needs. But in smaller hospitals, rural facilities, and community imaging centers with less purchasing leverage, shortages can result in outright procedure cancellations.
The ifosfamide shortage is concentrated at cancer centers and hospitals that treat testicular cancer, sarcoma, and pediatric cancers. Oncologists at these institutions are being forced to evaluate whether substitute regimens are appropriate, which often means using less well-studied alternatives or adjusting dosing in ways that carry their own risk and uncertainty.
The controlled substance shortage affects patients in chronic pain management programs and those with ADHD who depend on stimulant medications, both populations that are already vulnerable to care disruption and for whom medication gaps carry significant consequences.
What Doctors and Experts Say
"Just under half (48%) of all new shortages in 2026 are sole-source products (a single manufacturer)," ASHP noted in its Q2 data summary. "Ten percent of all new shortages in 2026 are contrast agents used for potentially life-saving procedures such as CT scans and MRIs."
The ASHP has consistently argued that the root cause of drug shortages is structural: the generic injectable drug market is organized in ways that undervalue supply resilience, reward cost-cutting over redundancy, and create conditions where a single manufacturer disruption can cascade into a national shortage. The economic framework for generic drug manufacturing does not automatically incentivize the kind of manufacturing diversity and reserve capacity that would prevent a sole-source disruption from eliminating national supply.
ASHP has recommended congressional action to create financial incentives for multi-source manufacturing of essential medications, establish strategic reserves for critical shortage-prone drugs, and strengthen FDA oversight of manufacturing quality at generic facilities.
What the Evidence Shows and What It Does Not
MedicalDaily Evidence Check
- Data source: ASHP (American Society of Health-System Pharmacists) and University of Utah Drug Information Service Q2 2026 drug shortage statistics
- Active shortages (Q2 2026): 227 — the third consecutive quarterly increase
- All-time high (comparison): 323 in Q1 2024
- 2024 year-end comparison: 271 at end of 2024
- Notable new shortage: Ifosfamide (chemotherapy for testicular cancer and sarcoma) — severe, due to manufacturing quality problems at a key supplier
- Sole-source proportion of new 2026 shortages: 48%
- Contrast agent proportion of new 2026 shortages: 10%
- Controlled substance proportion of active shortages: 16%
- What it shows: An active, upward-trending drug shortage environment with specific acute shortages in high-stakes oncology and diagnostic imaging categories
- What it does not show: Hospital-by-hospital supply levels, patient harm statistics directly attributed to the current shortage period, or timeline for resolution of specific shortages
- What readers should know: Patients who are currently on or expecting to start ifosfamide-containing regimens, or whose physician has ordered CT with contrast, should speak with their care team about current availability and any planned alternatives.
Who Is Most Affected?
The patients facing the most direct harm from current shortages include:
- Cancer patients awaiting or currently on ifosfamide-containing curative chemotherapy regimens (testicular cancer, sarcoma, Ewing sarcoma)
- Patients requiring CT or MRI with contrast for cancer staging, stroke evaluation, cardiac imaging, or pulmonary embolism assessment
- Patients managing chronic pain who depend on controlled substance prescriptions that may face delays
- People with ADHD whose stimulant medication prescriptions may be difficult to fill
- Any patient whose physician has prescribed a medication in active shortage and who has already encountered difficulty obtaining it
What You Can Do Now
- If you are a cancer patient whose treatment plan includes ifosfamide, ask your oncologist or infusion pharmacy directly about current availability and whether there is a substitute regimen being prepared as a contingency.
- If you have been told that a CT or MRI with contrast is being delayed due to supply, ask your physician whether the delay poses a clinical risk that should be escalated, or whether an alternative imaging modality (such as MRI without contrast or ultrasound) can provide comparable clinical information in the interim.
- If you take a controlled substance for chronic pain or ADHD, contact your pharmacy and prescriber at least a week in advance of your monthly refill to allow time for alternative sourcing if needed.
- Healthcare providers experiencing specific drug shortages can access current alternatives and management guidance through the ASHP drug shortage database and the University of Utah Drug Information Service.
- Patients who want to report a shortage impact to federal officials can contact the FDA's drug shortage staff or their congressional representatives, who have the authority to direct FDA to investigate or prioritize shortage resolution.
Cost and Access: What Patients Should Know
Drug shortages sometimes lead hospitals to use alternative agents that are more expensive, less well-studied, or not covered by the patient's insurance under the same terms as the originally prescribed drug. Patients who are switched to an alternative medication due to shortage should ask their prescriber to document the substitution and contact their insurance plan to confirm coverage of the substitute before the first administration.
For cancer patients whose treatment is being altered due to ifosfamide shortage, patient advocacy organizations including the American Cancer Society and the Testicular Cancer Awareness Foundation may be able to provide navigation support and information on alternative sourcing options.
What Happens Next
The ifosfamide shortage will be driven by the recovery timeline of the manufacturer's quality remediation, which is not publicly disclosed. ASHP and the FDA Drug Shortage Staff are expected to provide periodic updates. Contrast agent shortages are ongoing and driven by both supply and demand dynamics that have persisted since the 2022 initial shortage; resolution requires new manufacturing capacity or demand reduction strategies that take months to implement. MedicalDaily will report on shortage resolution announcements and any significant new entries to the active shortage list.
The Bottom Line
U.S. drug shortages rose to 227 in the second quarter of 2026, the third consecutive quarterly rise, with a severe new shortage of the testicular cancer and sarcoma chemotherapy drug ifosfamide, ongoing scarcity of CT and MRI contrast agents affecting diagnostic imaging, and persistent controlled substance shortages for chronic pain and ADHD patients. The underlying cause is structural: nearly half of all new shortages involve drugs made by only one manufacturer, and a single facility's quality failure eliminates national supply with no immediate backup. Patients on affected medications should speak with their care team about contingency planning now.
